Paper40480232
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.
Benton A and 11 others. Cancer Cell, 2025. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Papers, record 40480232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40480232
- Cell line
- HEK293T2,726 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records4
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Proto-Oncogene Proteins p21(ras) | Major topic |
| Mutation | Major topic |
| T-Lymphocytes | Major topic |
| Receptors, Antigen, T-Cell | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Xenograft Model Antitumor Assays | |
| Cell Line, Tumor | |
| Peptides | |
| Lung Neoplasms |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA260902 | NCI NIH HHS | United States | R01CA260902 | PubMed and NIH | NIH RePORTER |
| R01 EB026892 | NIBIB NIH HHS | United States | R01EB026892 | PubMed and NIH | NIH RePORTER |
| T32 GM008076 | NIGMS NIH HHS | United States | T32GM008076 | PubMed | NIH RePORTER |
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37938771 | Targeting of intracellular oncoproteins with peptide-centric CARs. | Nature | 2023 | https://conductscience.org/library/papers/37938771 | PubMed |
| 2 | 36203573 | IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. | Front Immunol | 2022 | https://conductscience.org/library/papers/36203573 | PubMed |
| 3 | 28676342 | Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. | Mol Ther | 2017 | https://conductscience.org/library/papers/28676342 | PubMed |
| 4 | 36732477 | Synapse-tuned CARs enhance immune cell anti-tumor activity. | Nat Biotechnol | 2023 | https://conductscience.org/library/papers/36732477 | PubMed |
| 5 | 29707912 | Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive "Empty" Molecules Rather than by the Supply of Peptide Ligands. | Proteomics | 2018 | https://conductscience.org/library/papers/29707912 | PubMed |
| 6 | 31501612 | Clinical lessons learned from the first leg of the CAR T cell journey. | Nat Med | 2019 | https://conductscience.org/library/papers/31501612 | PubMed |
| 7 | 36629052 | Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells. | Clin Transl Med | 2023 | https://conductscience.org/library/papers/36629052 | PubMed |
| 8 | 29055006 | Posttranscriptional Regulation of HLA-A Protein Expression by Alternative Polyadenylation Signals Involving the RNA-Binding Protein Syncrip. | J Immunol | 2017 | https://conductscience.org/library/papers/29055006 | PubMed |
| 9 | 7636241 | Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. | J Immunol | 1995 | https://conductscience.org/library/papers/7636241 | PubMed |
| 10 | 35474673 | Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. | Cell Rep Methods | 2021 | https://conductscience.org/library/papers/35474673 | PubMed |
| 11 | 29282079 | Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues. | BMC Cancer | 2017 | https://conductscience.org/library/papers/29282079 | PubMed |
| 12 | 31207478 | Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours. | Cancer Treat Rev | 2019 | https://conductscience.org/library/papers/31207478 | PubMed |
| 13 | 31142602 | Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. | J Immunol | 2019 | https://conductscience.org/library/papers/31142602 | PubMed |
| 14 | 29123084 | Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. | Nat Commun | 2017 | https://conductscience.org/library/papers/29123084 | PubMed |
| 15 | 21830940 | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21830940 | PubMed |
| 16 | 31798590 | Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. | Front Immunol | 2019 | https://conductscience.org/library/papers/31798590 | PubMed |
| 17 | 34936383 | An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. | Sci Transl Med | 2021 | https://conductscience.org/library/papers/34936383 | PubMed |
| 18 | 9326219 | Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. | Blood | 1997 | https://conductscience.org/library/papers/9326219 | PubMed |
| 19 | 30135176 | Tumor Antigen Escape from CAR T-cell Therapy. | Cancer Discov | 2018 | https://conductscience.org/library/papers/30135176 | PubMed |
| 20 | 29242379 | High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome. | Mol Cell Proteomics | 2018 | https://conductscience.org/library/papers/29242379 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42393377 | A guide to CAR T cell therapies: development, current status and future prospects. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/42393377 | PubMed |
| 42365891 | Multi-dimensional orchestration of binders for improved CAR-T immunotherapy. | Cancer Lett | 2026 | https://conductscience.org/library/papers/42365891 | PubMed |
| 42200804 | Targeted KRASG12V Degradation In Vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. | Cancer Res | 2026 | https://conductscience.org/library/papers/42200804 | PubMed |
| 42185131 | The evolution of display technologies for antibody drug discovery. | Trends Biotechnol | 2026 | https://conductscience.org/library/papers/42185131 | PubMed |
| 42078371 | A catalogue of missense and nonsense mutation abundances for the U.S. cancer patient population. | medRxiv | 2026 | https://conductscience.org/library/papers/42078371 | PubMed |
| 42039159 | CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42039159 | PubMed |
| 41977251 | Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977251 | PubMed |
| 41939454 | Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions. | Front Oncol | 2026 | https://conductscience.org/library/papers/41939454 | PubMed |
| 41930147 | Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future Perspectives. | Oncol Res | 2026 | https://conductscience.org/library/papers/41930147 | PubMed |
| 41719389 | KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. | Sci Adv | 2026 | https://conductscience.org/library/papers/41719389 | PubMed |
| 41635856 | Comprehensive analysis of IGFL1 in colorectal cancer and its promotion of tumour progression via inhibition of lipophagy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41635856 | PubMed |
| 41408054 | Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy. | Nat Commun | 2025 | https://conductscience.org/library/papers/41408054 | PubMed |
| 41354926 | Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41354926 | PubMed |
| 41309533 | Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/41309533 | PubMed |
| 40945517 | CAR-T cells in solid tumors: Challenges and breakthroughs. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/40945517 | PubMed |
| 40809405 | The next generation of dental treatments: Leveraging smart-responsive nanomaterials for unique oral environments. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40809405 | PubMed |
| 40672284 | A pan-cancer atlas of therapeutic T cell targets. | bioRxiv | 2025 | https://conductscience.org/library/papers/40672284 | PubMed |
| 40500372 | A cancer-causing mutation meets its match. | Nature | 2025 | https://conductscience.org/library/papers/40500372 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HLA-C | 3107 | PubTator's text mining | https://conductscience.org/library/genes/3107 | NCBI Gene |
| IL12B | 3593 | PubTator's text mining | https://conductscience.org/library/genes/3593 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40480232
GET https://conductscience.org/api/papers/v1/40480232/references?page=2